Opioid use disorder

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia

Retrieved on: 
Wednesday, April 3, 2024
Depression, Neurology, Schizophrenia, Patent, CFO, Opioid use disorder, OTCQB

The USPTO has issued U.S. Patent No.

Key Points: 
  • The USPTO has issued U.S. Patent No.
  • 11,793,801 entitled, “Treatment of Pain and Neurological Conditions”.
  • The patent is directed towards the use of a compound and composition and/or dosage form for treating pain, depression, and schizophrenia.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., and President, and Chairman of BioCorRx Pharmaceuticals Inc., commented, “The patented invention may offer a novel approach to reducing the severity of withdrawal symptoms for opioid use disorder compared to current standards of care."

BioCorRx Reports Business Update for 2023

Retrieved on: 
Tuesday, April 2, 2024
Annual report, Substance abuse, Bupropion, CFO, Risk, Public, OUD, Research, Security (finance), Opioid use disorder, NIH, Naltrexone, Bangladesh Technical Education Board, MUD, OTCQB, Pharmaceutical industry

ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.

Key Points: 
  • ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.
  • Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid use disorder (OUD).
  • We successfully decreased our total operating expenses by over $1.0 million for the year ending December 31, 2023, compared to the previous year.
  • Overall, we are optimistic about the business outlook and look forward to continuing to develop medicines.

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Retrieved on: 
Tuesday, April 2, 2024
Research, Frost, Patent, Partnership, Patient, OUD, G&A, Opioid use disorder, Addiction, GLEN, Consultant, Pharmaceutical industry

GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.

Key Points: 
  • GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023.
  • Specifically, we conducted meetings and received favorable feedback from both US and European regulators, allowing us to refine our clinical development plan.
  • Cash and cash equivalents were $2.8 million as of December 31, 2023, compared to $4.0 million as of December 31, 2022.
  • Net Loss was $5.1 million for the year ended December 31, 2023, compared to a net loss of $12.7 million for the year ended December 31, 2022.

Foundation for Opioid Response Efforts (FORE) Announces $1.4 Million Grant to Equal Justice Works to Launch National Legal Fellowship Program

Retrieved on: 
Thursday, March 21, 2024
Employment, Legal aid, Organization, Health, Education, Child, Opioid use disorder, Equal Justice Works, Housing, Lawyer, MPH, Opioid, Equal justice under law, Private law, Nursing

New York, March 21, 2024 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) today announced it is awarding a grant of $1,361,005 over 30 months to Equal Justice Works to launch a national Opioid Crisis Response Legal Fellowship Program that will address the legal consequences of the opioid crisis.

Key Points: 
  • New York, March 21, 2024 (GLOBE NEWSWIRE) -- The Foundation for Opioid Response Efforts (FORE) today announced it is awarding a grant of $1,361,005 over 30 months to Equal Justice Works to launch a national Opioid Crisis Response Legal Fellowship Program that will address the legal consequences of the opioid crisis.
  • “The opioid crisis cannot be fully addressed without multidisciplinary interventions, including legal assistance,” said Karen A. Scott, MD., MPH, President of FORE.
  • “We thank the Foundation for Opioid Response Efforts for their generous grant,” said Verna Williams, CEO of Equal Justice Works.
  • “FORE’s support will mobilize six Equal Justice Works Fellows to address critical legal needs frequently arising from opioid use disorder, such as child custody matters, housing, healthcare, and employment.

Innovative, high-quality research to benefit all Canadians gets major investment

Retrieved on: 
Wednesday, March 13, 2024
Health, Government, Brain, Transport, MRI, CFI, Wheelchair, Environment, Disease, Partnership, COVID-19, PET, The Honourable, Research, Infrastructure, University, Opioid use disorder, Student, Investment, Quebec lieutenant, Disability, Medicine, Snow, Renewable energy

He made the announcement on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry.

Key Points: 
  • He made the announcement on behalf of the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry.
  • The funding will support 100 infrastructure projects at 32 postsecondary institutions and research hospitals across the country and will help Canada remain at the forefront of exploration, discovery and innovation.
  • Other exceptional research infrastructure projects this funding supports include:
    Repurposing drugs to treat opioid use disorder.
  • Researchers will collaborate with people with lived experience of opioid use to repurpose existing drugs to treat the disorder’s debilitating symptoms.

Middlesex Recovery Earns Three-Year CARF Accreditation

Retrieved on: 
Tuesday, March 12, 2024
Health, Organization, Opioid use disorder, Commission, Senior counsel, CARF, Accreditation, Person, Nursing

LEWISVILLE, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Middlesex Recovery is proud to announce that it has earned a Three-Year Accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF) for its Office-Based Opioid Treatment: Addictions Pharmacotherapy (Adults) programs, located in Chelmsford, Gloucester, Norton, Stoughton, Woburn, MA and Salem, NH.

Key Points: 
  • LEWISVILLE, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Middlesex Recovery is proud to announce that it has earned a Three-Year Accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF) for its Office-Based Opioid Treatment: Addictions Pharmacotherapy (Adults) programs, located in Chelmsford, Gloucester, Norton, Stoughton, Woburn, MA and Salem, NH.
  • This designation represents the highest level of recognition that can be given to an organization and shows Middlesex Recovery’s substantial conformance to the CARF standards.
  • An organization receiving a Three-Year Accreditation has gone through a rigorous peer-review process.
  • Middlesex Recovery is managed by BayMark Health, with treatment centers in Massachusetts and southern New Hampshire.

YesCare has Joined Leading Multiagency Initiative on Opioid Use

Retrieved on: 
Tuesday, April 2, 2024
Public Policy, Government, Law Enforcement, Emergency Services, Mental Health, State, Local, Health, Managed Care, General Health, Mental health, Policy, SAMHSA, Partnership, ADOC, Prison, MAT, Public, Patient, Recidivism, Psychological abuse, Opioid use disorder, Federal Prison Camp, Pensacola, Senior counsel, Lean Six Sigma, Opioid, Substance Abuse, Nursing

This multiagency initiative focused on Medication Assisted Treatment (MAT) in prisons will be a collaboration led by SAMHSA (the federal agency charged with advancing behavioral health since 1992) along with YesCare, ADOC, the Alabama Department of Mental Health, the Alabama Board of Pardons and Parole, and the State Opioid Treatment Authority.

Key Points: 
  • This multiagency initiative focused on Medication Assisted Treatment (MAT) in prisons will be a collaboration led by SAMHSA (the federal agency charged with advancing behavioral health since 1992) along with YesCare, ADOC, the Alabama Department of Mental Health, the Alabama Board of Pardons and Parole, and the State Opioid Treatment Authority.
  • The Policy Academy is a part of the Biden-Harris Administration's efforts to address the opioid overdose epidemic and to support recovery among Americans experiencing substance use disorders.
  • “Through this partnership, Alabama will be on the leading edge of MAT implementation, and success here will allow for an optimized roll out of improved programs nationwide,” said Jeff Sholey, CEO of YesCare.
  • “To be selected by SAMHSA for this initiative reflects a true testament to the partnership we share with ADOC, and the common dedication we have in helping those with Opioid Use Disorders.

Aleve® Speaks The Painful Truth, Encouraging Consumers to Explore Their Pain Management Options

Retrieved on: 
Monday, March 25, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Aromatherapy, National Consumers League, Hydrocodone, MAPDA, NCL, Partnership, Mother, Education, Patient, Yoga, Paracetamol, Opioid use disorder, Naproxen, Trial of the century, Bayer, Meditation, OTC, CDC, Love, Pain, Multimedia, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240325938118/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240325938118/en/
    Aleve launches "The Painful Truth" campaign with Mothers Against Prescription Drug Abuse (MAPDA) and National Consumers League (NCL).
  • (Photo: Business Wire)
    While opioid dispensing rates in the U.S. are slowly ticking down, they remain elevated compared with rates in other countries.
  • “The Painful Truth” campaign launches with a three-minute film featuring real pain sufferers who are at crossroads in their pain relief journeys and seeking guidance.
  • At this critical juncture in their care, the patients are encouraged to consider different pain relief options.

Battling the opioid epidemic: New research shows access to opioid use disorder treatment in emergency rooms saves lives

Retrieved on: 
Tuesday, March 26, 2024
JAMA, EDS, American Medical Association, Survival, Addiction medicine, AHS, Patient, OUD, Journal, Research, Buprenorphine, Opioid use disorder, Emergency department, Drug, ED, Alameda Health System, Pharmaceutical industry

The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.

Key Points: 
  • The research points to emergency rooms as critical gateways for providers to reach and treat patients with opioid use disorder.
  • Emergency departments are often the lowest-barrier access point for people seeking immediate health care.
  • This research shows that initiation of buprenorphine in the emergency department, combined with linkage to outpatient treatment, saves lives.
  • The Bridge Clinic at AHS is at the forefront of bringing opioid use disorder treatment to patients in Alameda County.

Collaboration with Ophelia Provides Highmark Wholecare Members Collaboration With Access to Opioid Use Disorder Treatment

Retrieved on: 
Wednesday, March 20, 2024
Psychiatry, Addiction medicine, Education, Patient, MAT, OUD, Travel, Buprenorphine, Prescription, Death, Opioid use disorder, Methadone, Drug, CDC, Medicaid, Medicare, Food, Fentanyl, Pharmaceutical industry

Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.

Key Points: 
  • Ophelia has been part of Highmark Wholecare parent company Highmark Health's network in Pennsylvania since July 2021, serving 2.9 million commercial members.
  • In addition to treatment deserts and localized provider shortages, people with OUD tend to experience financial hurdles when seeking treatment.
  • "Highmark Wholecare's collaboration with Ophelia is helping course correct this crisis by providing access to comprehensive OUD care that our Medicaid and D-SNP members can receive quickly and safely."
  • "Our expanded collaboration with Highmark Health through Highmark Wholecare members allows us to serve communities that continue to be severely impacted by the opioid epidemic," said Zack Gray , CEO and co-founder at Ophelia.